





RealRate

PHARMACEUTICAL 2017

Seres Therapeutics Inc.
Rank 155 of 292



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Seres Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 63% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	198,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,457
Liabilities, Non-Current	0
Other Assets	38,152
Other Compr. Net Income	-179
Other Expenses	0
Other Liabilities	109,558
Other Net Income	1,260
Other Revenues	21,766
Property and Equipment	36,125
Research and Development	81,989
Selling, General and Administrative Expense	32,616

Output Variable	Value in 1000 USD
Assets	272,646
Liabilities	140,015
Expenses	114,605
Revenues	21,766
Stockholders Equity	132,631
Net Income	-91,579
Comprehensive Net Income	-91,668
Economic Capital Ratio	66%